Cancer-causing MAP2K1 mutation in a mosaic patient with cardio-facio-cutaneous syndrome and immunodeficiency

Area of Science:

• Genetics
• Molecular Biology
• Developmental Biology

Background:

• RASopathies are genetic disorders stemming from mutations in the RAS/mitogen-activated protein kinase (MAPK) pathway.
• These syndromes are characterized by developmental delays, distinct facial features, organ defects, and an increased risk of cancer.
• Somatic mutations in the RAS/MAPK pathway are a major driver of cancer development.

Observation:

• Germline mutations linked to cancer are typically presumed to be embryonically lethal.
• Previous studies in model organisms showed more severe phenotypes for cancer-associated MAP2K1 mutations compared to RASopathy mutations.
• A case study identified a patient with RASopathy harboring a cancer-associated MAP2K1 mutation (p.Phe53Leu).

Findings:

• The patient presented with RASopathy phenotype despite carrying a MAP2K1 mutation usually associated with cancer.
• The MAP2K1 p.Phe53Leu mutation was found to be postzygotically mosaic.
• This mosaicism is proposed as the mechanism allowing for patient survival.

Implications:

• Postzygotic mosaicism can mitigate the severity of mutations in developmental pathways.
• This finding expands the understanding of genotype-phenotype correlations in RASopathies and cancer predisposition.
• It suggests a potential mechanism for survival in individuals with seemingly lethal mutations.